News

- OncoDNA’s personalised cancer profiling tests covered by a new insurer
- Nov. 13, 2019
- read more

- GASTROINTESTINAL CANCER: Promising results from a small phase Ib study of regorafenib + nivolumab in advanced gastric or colorectal cancer: ORR 44% & 36% respectively.
- June 29, 2020
- read more
- BLADDER CANCER: In a retrospective analysis, both ARID1A mutation and CXCL13 expression showed positive correlation with response to checkpoint inhibition, including overall survival. Combining the markers improved prediction.
- June 29, 2020
- read more
- DRUG TARGETS: A novel ATR inhibitor has cleared phase I development with manageable toxicity; responses were seen in tumours harbouring ATM/ARID1A and BRCA1 alteration (colorectal and ovarian respectively).
- June 29, 2020
- read more
- COVID-19 PANDEMIC: Clinical trial enrolment has been hard hit with WCG's international tracking system indicating only 11% of sites open to recruitment late April/early May, rising to 30% last week.
- June 29, 2020
- read more
- COVID-19 PANDEMIC: Modelling from the US National Cancer Institute (NCI) predicts the pandemic will result in an excess of over 10,000 deaths from breast and colorectal cancer in the USA, due to missed screening and delayed therapy.
- June 29, 2020
- read more
- CANCER PREVENTION The American Cancer Society (ACS) have updated their diet and physical exercise guidelines to advise avoidance of all alcohol, a change from previous guidance advising moderation.
- June 22, 2020
- read more
- BREAST CANCER For newly diagnosed ER+ disease, neoadjuvant anti-oestrogen therapy may be an acceptable bridge to surgery in the face of COVID-19 related delays.
- June 22, 2020
- read more
- RENAL CANCER In a retrospective analysis, rechallenge with immunotherapy delivered ORR 23% (compared with 37% ORR for first exposure); responses at rechallenge were not restricted to those who had responded at first exposure.
- June 22, 2020
- read more
- LYMPHOMA The FDA have approved the EZH2 inhibitor tazemetostat in folliciular lymphoma, third line for EZH2-mutant disease, or where there are no other treatment options for EZH2 wild-type disease [...]
- June 22, 2020
- read more
- LUNG CANCER Using genomic analysis to ascertain loss of heterozygosity at the HLA locus in combination with tumour mutational burden (TMB) provided better prediction of response to immunotherapy compared with TMB alone.
- June 22, 2020
- read more
- IMMUNOTHERAPY The FDA have granted pan-cancer approval for the PD-1 inhibitor pembrolizumab for cancers with tumour mutational burden >10 mut/mb, adult and paediatric.
- June 22, 2020
- read more
- COVID-19 PANDEMIC Urgent referrals for suspected cancer were down 60% in April in the UK; some cancer types were differentially affected with suspected breast cancer referrals down 78%.
- June 22, 2020
- read more
- CHOLANGIOCARCINOMA A small single arm study of PD-1 inhibition (nivolumab) for previously treated biliary tract cancers showed ORR 11%
- May 26, 2020
- read more
- HEPATOCELLULAR CANCER Combination PD-L1 and VEGFR inhibition (atezolizumab plus bevacizumab) delivered better overall and progression-free survival than standard of care sorafenib in a pivotal phase 3 study.
- May 26, 2020
- read more
- MELANOMA: In a retrospective study of patients with advanced disease who achieved a complete response to immunotherapy, cessation of therapy was associated with a 27% risk of subsequent disease progression.
- May 26, 2020
- read more
- PROSTATE CANCER The FDA have granted accelerated approval to the PARP inhibitor rucaparib for BRCA-mutated (germline or somatic) metastatic castrate-resistant disease.
- May 26, 2020
- read more
- PROSTATE CANCER: A PROTAC-based androgen receptor degrader has shown anti-tumour activity in first in human studies presented at ASCO.
- May 26, 2020
- read more
- DRUG TARGETS: KRAS Disappointing results from ASCO of the KRAS G12C inhibitor (AMG-510), with a study in colorectal cancer and a basket study of non-NSCLC/CRC indications both delivering ORR 12%.
- May 26, 2020
- read more
- DRUG TARGETS: MET A phase I study of an anti-MET antibody (telisotuzumab) in advanced cancers reported partial responses in MET amplified tumours
- May 26, 2020
- read more
- 47% of cancer overall positive response to treatment thanks to OncoDEEP combined tumour molecular profiling
- May 11, 2020
- read more
- EARLY CANCER DETECTION: Data from GRAIL presented at AACR indicate continued progress in the development of a methylation-based ctDNA assay with high specificity for the early detection of cancer.
- May 11, 2020
- read more
- PANCREATIC CANCER: Addition of a PARP inhibitor (veliparib) to gemcitabine + cisplatin chemo did not improve outcomes for patients harbouring germline mutations in BRCA1/2 or PALB2.
- May 11, 2020
- read more
- MELANOMA: The addition of PD-L1 blockade (atezolizumab) to combined BRAF/MEK inhibition (vemurafenib + cobimetinib) improved PFS as first line therapy in advanced BRAF V600 mutant melanoma. Survival data are awaited.
- May 11, 2020
- read more
- GASTRIC/COLORECTAL CANCER: Promising early efficacy data for combined regorafenib plus nivolumab: ORR 44% and 36% for gastric and colorectal respectively, all bar one with microsatellite stable disease.
- May 11, 2020
- read more
- CHOLANGIOCARCINOMA: Phase 2 data now published supporting the FDA's recent approval of pemigatinib for previously treated advanced FGFR2-rearranged tumours (ORR 36%). Responses were not seen in subjects with other FGF/FGFR alterations
- May 11, 2020
- read more
- LUNG CANCER: Data from TRACERx presented at AACR provides further support for the use of personalised ctDNA assays in the assessment of minimal residual disease and impending progression following surgery for early stage disease.
- May 11, 2020
- read more
- LUNG CANCER: The FDA have approved the MET inhibitor capmatinib for advanced NSCLC harbouring MET exon 14 skipping. Approval is based on ORR of 68% and 41% for treatment-naive and previously treated patients, respectively.
- May 11, 2020
- read more
- IMMUNOTHERAPY 29% of patients with immune-related side-effects requiring therapy cessation experienced recurrence of the same SE on rechallenge.
- May 4, 2020
- read more
- DRUG TARGETS Disappointing results from NCI-MATCH where the MEK inhibitor trametinib failed to impact cancers harbouring non-V600 BRAF mutations (ORR 3%).
- May 4, 2020
- read more
- ENDOMETRIAL CANCER: Normal endometrial glands frequently harbour pathogenic somatically-acquired mutations in cancer genes, suggesting that the processes leading to cancer are initiated early in life.
- May 4, 2020
- read more
- BREAST CANCER: The FDA have granted accelerated approved to the anti-TROP2 antibody-drug conjugate sacituzumab govitecan for patients with triple negative disease.
- May 4, 2020
- read more
- Loss of CDK12 as a marker of aggressive disease likely to metastasise, but with higher response rates to checkpoint inhibition
- May 4, 2020
- read more
- PROSTATE CANCER: Structural variants resulting in rearrangement of the androgen receptor (AR) are frequent and may be a marker of resistance to endocrine therapy.
- May 4, 2020
- read more
- PROSTATE CANCER: Coexisting loss of BRCA2 and RB1 is associated with aggressive clinical behaviour in prostate cancer, and possibly also in other cancer types.
- May 4, 2020
- read more
- COVID-19: A fall in the number of people being diagnosed with cancer in recent weeks has been reported in several countries,
- May 4, 2020
- read more
- DRUG TARGETS: IMMUNOTHERAPY - Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms
- April 27, 2020
- read more
- DRUG TARGETS: NTRK - The UK regulator NICE has approved the use of larotrectinib for patients with advanced NTRK fusion position solid tumours, in both adults and children.
- April 27, 2020
- read more
- COLORECTAL CANCER: A small neoadjuvant study reported responses to combined PD-L1 + CTLA-4 blockade in both MSI+ (100% pathological response, 95% MPR) and MSI-negative (27% pathological response, 20% MPR) tumours.
- April 27, 2020
- read more
- BREAST CANCER: Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
- April 27, 2020
- read more
- BREAST CANCER: Updated ASCO/CAP guidelines for oestrogen receptor testing highlight the weak positive group (1-10% ER+ tumour cells) as requiring specific pathways for laboratory confirmation and discussion of therapeutic options
- April 27, 2020
- read more
- ENDOMETRIAL CANCER: Data from SGO 2020 indicate survival benefit for the addition of trastuzumab to standard chemo for those with advanced ERBB2-expressing (HER2+) disease (OS 24.4 versus 29.6 months)
- April 27, 2020
- read more
- CHOLANGIOCARCINOMA: FGFR2 fusions appear to be much less frequent in tumours arising in the context of chronic liver fluke infection, the most common aetiology in SE Asia.
- April 27, 2020
- read more
- CHOLANGIOCARCINOMA: The FDA have granted accelerated approval to the FGFR inhibitor pemigatinib for previously treated patients with advanced FGFR2-rearranged tumours. The pivotal clinical trial showed ORR 36% for this agent.
- April 27, 2020
- read more
- BREAST CANCER : The broad spectrum kinase inhibitor lucitanib (VEGFR1-3, FGFR1-3 & PDGFRα/β) showed modest efficacy in FGFR1 amplified HR+ disease, delivering ORR 19%, at the cost of hypertension-related toxicity.
- April 20, 2020
- read more
- PANCREATIC CANCER : In a real-world study, 28% of patients harboured actionable genomic variants, of whom 24% received molecularly matched therapy. Receipt of matched therapy was associated with longer OS (2.6 versus 1.5 years).
- April 20, 2020
- read more
- COLORECTAL CANCER : The FDA have approved combination therapy targeting BRAF and EGFR (encorafenib + cetuximab) for metastatic BRAF V600E mutant colorectal cancer which has previously been treated.
- April 20, 2020
- read more
- COVID-19 PANDEMIC: The American Society of Clinical Oncology (ASCO) has launched a registry to gather information on disease severity and outcomes for cancer patient
- April 20, 2020
- read more
- CANCER SCREENING & EARLY DETECTION: A methylation based ctDNA assay from GRAIL delivered sensitivity 93% for stage IV cancer, falling to 43% for stage II and 18% for stage I disease
- April 14, 2020
- read more
- NTRK FUSIONS: A pooled analysis of 3 clinical trials (n=50 total subjects) indicated ORR 79% for the NTRK inhibitor larotrectinib, with 16% CR
- April 14, 2020
- read more
- MELANOMA Protein kinase C is being explored as a drug target in uveal melanoma, where it is activated by upstream mutations in GNAQ/GNA11
- April 14, 2020
- read more
- BREAST CANCER: Real-world data from the GENIE consortium suggest a benefit for MTOR inhibition where tumours harbour an AKT E17K mutation.
- April 14, 2020
- read more
- CNS CANCER: Evolution of mismatch repair deficiency renders glioblastoma resistant to temozolomide (TMZ)
- April 14, 2020
- read more
- SARCOMA: The oncolytic virus T-VEC in combination PD-1 blockade (pembrolizumab) delivered ORR 35% in advanced sarcoma (Phase 2, n=20 subjects). Further development is planned.
- April 6, 2020
- read more
- BREAST CANCER: Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
- April 6, 2020
- read more
- LUNG CANCER: Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- April 6, 2020
- read more
- LUNG CANCER: The FDA have granted breakthrough designation to an EGFR-MET bispecific antibody from Janssen, for the treatment of NSCLC harbouring an EGFR exon 20 insertion mutation.
- April 6, 2020
- read more
- LUNG CANCER: A meta-analysis of osimertinib treatment for brain metastasis reported CNS ORR 64%.
- April 6, 2020
- read more
- OVARIAN CANCER: All-comer testing of tumour (FFPE) tissue for BRCA1/2 mutations reported a pickup rate of 17% for pathogenic variants; follow-up germline testing revealed mutations to be 57% inherited and 43% somatic.
- April 6, 2020
- read more
- COLORECTAL CANCER: The addition of cetuximab to perioperative chemotherapy resulted in worse overall survival compared with chemo alone in KRAS wild-type patients with resectable/suboptimally resectable liver metastases.
- March 30, 2020
- read more
- COLORECTAL CANCER: Colorectal cancer statistics, 2020
- March 30, 2020
- read more
- SARCOMA: Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma
- March 30, 2020
- read more
- LUNG CANCER: Combination MET + EGFR inhibition (osimertinib + savolitinib) delivered ORR 48-64% in EGFR-mutant, MET-amplified subjects who had progressed on prior anti-EGFR therapy.
- March 30, 2020
- read more
- LUNG CANCER: Real-world data suggests osimertinib is associated with a 5% risk of cardiac adverse events. This drug has previously been linked to QT prolongation, cardiomyopathy and heart failure.
- March 30, 2020
- read more
- COVID-19 PANDEMIC : ASCO have released guidance on dealing with the impact of the pandemic on the delivery of cancer care.
- March 30, 2020
- read more
- DRUG RESISTANCE: In vitro preclinical studies identified BRCA2 amplification as a potential mechanism of PARP inhibitor resistance in BRCA2 mutant cancer cell lines.
- March 16, 2020
- read more
- CANCER SCREENING AND EARLY DETECTION: Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients
- March 16, 2020
- read more
- B-CELL LYMPHOMA: Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies
- March 16, 2020
- read more
- PANCREATIC CANCER: An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice
- March 16, 2020
- read more
- COLORECTAL CANCER: Mutations in TP53 and RAS/BRAF show utility as prognostic markers, with co-mutated tumours showing the worst outcomes.
- March 16, 2020
- read more
- Multi-targeted CRISPR-based genome engineering has been used to successfully generate adoptive anti-cancer T cells. The T cells express an NY-ESO-1 transgene alongside deletion of both PD-1 and the endogenous T cell receptor.
- March 9, 2020
- read more
- CLINICAL TRIALS AND DRUG TARGETS: CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
- March 9, 2020
- read more
- CLINICAL TRIALS AND DRUG TARGETS: Oncology indications are set to dominate the landscape in 2020, accounting for 32% of all new trials.
- March 9, 2020
- read more
- MELANOMA: Two noteworthy biomarker studies identified assessment of T cell infiltrate and clonality as a predictor of subsequent metastasis in early stage disease.
- March 9, 2020
- read more
- BREAST CANCER: FDA approves neratinib for metastatic HER2-positive breast cancer
- March 9, 2020
- read more
- BREAST CANCER: Adjuvant cisplatin was not superior to doxorubicin-cyclophosphamide at inducing pathological CR for patients with BRCA1/2 mutant disease in a small cohort (n=117).
- March 9, 2020
- read more
- LUNG CANCER: A study of patients with locally advanced NSCLC identified potential utility for personalised ctDNA-based MRD detection in guiding the use of consolation immunotherapy.
- March 9, 2020
- read more
- DRUG TARGETS: The heat shock protein 90 inhibitor ganetespib failed to improve outcomes when added to chemotherapy in advance NSCLC (phase III GALAXY-2 trial). Samples were obtained for biomarker studies; results not yet reported.
- March 2, 2020
- read more
- PHARMACOGENOMICS: The FDA have published a provisional list of PGx markers with potential utility in clinical practice, and are inviting comments from the community.
- March 2, 2020
- read more
- BREAST CANCER: ARID1A loss of function was identified as a marker of resistance to hormone therapy and of sensitivity to BET inhibition in this study of preclinical models and patient samples.
- March 2, 2020
- read more
- BREAST CANCER: RB1 loss by IHC was associated with sensitivity to the TOPO 1 inhibitor irinotecan in a preclinical TNBC model. Confirmation of this association in patient samples would be a useful next step.
- March 2, 2020
- read more
- BLADDER CANCER: Durvalumab Plus Olaparib Combo Shows 50% Pathologic Complete Response in MIBC
- Feb. 24, 2020
- read more
- LUNG CANCER: FDA Grants Priority Review to NDA for Capmatinib in MET Exon 14+ NSCLC
- Feb. 24, 2020
- read more
- MELANOMA CTLA-4 inhibition (ipilimumab) improved overall survival compared with interferon in the adjuvant setting. A higher dose of ipilimumab (10 mg/kg versus 3 mg/kg) produced more adverse events but did not further improve outcome
- Feb. 24, 2020
- read more
- PROSTATE CANCER: Combined PD-L1 and multi-kinase inhibition (atezolizumab + cabozantinib) produced ORR 32% in a small (n=44) study of metastatic castrate-resistant disease; two subjects achieved CR (COSMIC-021 trial, ASCO GU 2020).
- Feb. 24, 2020
- read more
- BREAST CANCER: 53% of patients receiving neoadjuvant PARP inhibition (talazoparib) achieved complete pathological response in this small (n=20) study of germline BRCA1/2 mutant patients. A larger trial is underway.
- Feb. 24, 2020
- read more
- CERVICAL CANCER: Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study
- Feb. 24, 2020
- read more
- LUNG CANCER: Osimertinib demonstrated efficacy in EGFR-mutant NSCLC with CNS metastasis, delivering 62% CNS ORR in a small (n=41) study.
- Feb. 24, 2020
- read more
- GERMLINE CANCER PREDISPOSITION: Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness
- Feb. 17, 2020
- read more
- LYMPHOMA: A phase 1/2 trial of anti-CD19 CAR transduced natural killer (CAR-NK) cells demonstrated efficacy in lymphoid malignancy without the CNS side-effects or production complexity of CAR-T approaches.
- Feb. 17, 2020
- read more
- COLORECTAL CANCER: A giant inflatable colon has been deployed by a team in the Lebanon to raise cancer awareness and encourage participation in screening programmes. Positive outcomes were reported.
- Feb. 17, 2020
- read more
- LUNG CANCER: Studies of patient biopsies and preclinical models imply that activating EGFR mutations drive an immunosuppressive tumour microenvironment, and suggest synergy for combination EGFR/PD-1 inhibition.
- Feb. 17, 2020
- read more
- ENDOMETRIAL CANCER: The combination of everolimus, letrozole and metformin delivered OR 28% (all PR) in pretreated patients in this small (n=54) phase II study.
- Feb. 17, 2020
- read more
- LUNG CANCER: Unsurprisingly, bronchial cells from smokers harbour more frequent mutations than non-smokers; reassuringly, quitting smoking allows replenishment of the lung epithelium by quiescent cells with lower mutational burden.
- Feb. 10, 2020
- read more
- LUNG CANCER: Screening current and former smokers by CT scanning reduced lung cancer mortality by 0.8 deaths per 1,000 person-years in a Dutch study with 10 years follow up.
- Feb. 10, 2020
- read more
- BREAST CANCER: Whilst high dose chemo with blood stem cell rescue is ineffective in advanced disease (and mired in scandal following the misconduct of Bezwoda and colleagues in the 1990's), this approach may benefit high-risk patients
- Feb. 10, 2020
- read more
- BREAST CANCER: Preclinical and patient studies have identified loss of either RB1 or PTEN as mechanisms of resistance to CDK4/6 inhibitors such as palbociclib. PTEN loss also confers resistance to PI3K inhibitors such as taselisib.
- Feb. 10, 2020
- read more
- BREAST CANCER: Aneuploidy and a deregulated DNA damage response suggest haploinsufficiency in breast tissues of BRCA2 mutation carriers
- Feb. 10, 2020
- read more
- BREAST CANCER: A small study identified somatic ATM mutation as a predictor of response to radiotherapy. This association is in keeping with known ATM pathway biology and warrants further study.
- Feb. 10, 2020
- read more
- IMMUNOTHERAPY Three studies have identified tumour B-cell infiltration as an independent marker of response to check-point inhibition therapy.
- Jan. 27, 2020
- read more
- BREAST CANCER: Several new anti-HER2 agents on the horizon
- Jan. 27, 2020
- read more
- LUNG CANCER: The addition of chemotherapy to EGFR inhibitor therapy improved survival in advanced EGFR-mutant NSCLC in two independent studies, compared with targeted therapy alone
- Jan. 27, 2020
- read more
- PROSTATE CANCER: The FDA have granted priority review for the PARP inhibitor rucaparib in the mCRPC setting, based on data from the phase II TRITON2 trial which showed ORR 43.9% for BRCA1/2 mutation carriers.
- Jan. 27, 2020
- read more
- LUNG CANCER: The FDA have granted priority review for combination nivolumab/ipilimumab (anti-PD-1/CTLA-4) as first line in advanced NSCLC (EGFR/ALK wt)
- Jan. 27, 2020
- read more
- LUNG CANCER: Crizotinib delivered objective response rates of 32% in a phase I study of NSCLC harbouring MET exon 14 skipping, most of whom (62%) had received prior therapy.
- Jan. 27, 2020
- read more
- COLORECTAL CANCER: The FDA have approved the kinase inhibitor avapritinib for patients with metastatic gastrointestinal stromal tumour (GIST) harbouring a PDGFRA exon 18 mutation
- Jan. 20, 2020
- read more
- LUNG CANCER: Correcting for tumour cellularity can improve the power of tumour mutational burden to identify immunotherapy responders
- Jan. 20, 2020
- read more
- COLORECTAL CANCER: Recent work in colorectal cancer supports a role for ctDNA methylation patterns as a tumour-specific marker.
- Jan. 6, 2020
- read more
- GERMLINE CANCER: PREDISPOSITION An international 524 family study of pathogenic PALB2 variants identified increased risk of developing breast, ovarian and pancreatic cancers.
- Jan. 6, 2020
- read more
- HEPATOCELLULAR CANCER: The FGFR4 inhibitor fisogatinib produced ORR 17% for FGF19+ tumours (IHC); responses were not seen in FGF19-negative cases. Resistance was associated with the appearance of gatekeeper mutations.
- Jan. 6, 2020
- read more
- COLORECTAL CANCER: Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer
- Jan. 6, 2020
- read more
- MELANOMA: Ipilimumab (anti-CTLA-4) improved survival compared to interferon in the adjuvant setting.
- Jan. 6, 2020
- read more
- LUNG CANCER: Overweight patients achieve better responses to checkpoint inhibition.
- Jan. 6, 2020
- read more
- BREAST CANCER: Conflicting results of neoadjuvant immunotherapy for TNBC, (PD-1 inhibitor pembrolizumab vs atezolizumab)
- Dec. 30, 2019
- read more
- PANCREATIC CANCER: An FDA panel will recommend approval of olaparib as maintenance for patients with platinum sensitive/stable disease, based on data from the POLO trial.
- Dec. 30, 2019
- read more
- LUNG CANCER: The kinase inhibitor crizotinib produced ORR 27% for patients with MET exon 14 skipping or amplification in a small (n=26) early phase study
- Dec. 30, 2019
- read more
- CLINICAL TRIALS: Patients enrolled in therapeutic trials for the most common cancer types are on average 6.5 years younger than the incident population
- Dec. 30, 2019
- read more
- CANCER HETEROGENEITY: Longitudinal molecular trajectories of diffuse glioma in adults
- Dec. 23, 2019
- read more
- COLORECTAL CANCER: Genomic Profiling for KRAS, NRAS, BRAF, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer
- Dec. 23, 2019
- read more
- BREAST CANCER: ACMG have issued guidance against testing all patients with breast cancer for inherited predisposition; rather, they favour careful case-by-case assessment of risk
- Dec. 23, 2019
- read more
- BREAST CANCER: NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+
- Dec. 23, 2019
- read more
- BREAST CANCER: Two new agents show promising clinical results in HER2+ disease: trastuzumab deruxtecan, an antibody-drug conjugate, and tucatinib, a small molecule inhibitor.
- Dec. 23, 2019
- read more
- Immune editing (resulting in loss of neoantigens) has been suggested as a mechanism of tumour immune escape.
- Dec. 20, 2019
- read more
- A small NCI-MATCH study of PD-1 inhibition (nivolumab) in non-CRC MSI+ tumours showed ORR 36%.
- Dec. 20, 2019
- read more
- IMMUNOTHERAPY Single agent pembrolizumab (aPD-1) failed its primary OS/PFS end-point in a phase 3 trial of previously treated hepatocellular cancer, and showed minimal activity (3-5% ORR) in treatment refractory prostate cancer.
- Dec. 20, 2019
- read more
- MELANOMA Pre-clinical work suggests potential utility of combined BRAF/MEK inhibition for BRAF wild-type, NRAS mutant melanoma.
- Dec. 20, 2019
- read more
- LYMPHOMA: Several studies from ASH reported significant activity and impressive response rates for different bispecific antibodies (mainly CD3 and CD19 or CD20).
- Dec. 16, 2019
- read more
- PANCREATIC CANCER The FDA will discuss this month an application for approval of the PARP inhibitor olaparaib as maintenance therapy for patients with BRCA-mutant cancer post upfront chemotherapy.
- Dec. 16, 2019
- read more
- CERVICAL CANCER: A vision for the global elimination of cervical cancer through systematic international vaccination programmes.
- Dec. 16, 2019
- read more
- UROTHELIAL CANCER: Pathogenic or likely pathogenic germline variants were found in 14% of patients with bladder cancer, mainly in DNA damage response genes.
- Dec. 16, 2019
- read more
- CHOLANGIOCARCINOMA The FDA have granted priority approval review of pemigatinib for patients harbouring FGFR2 fusions.
- Dec. 9, 2019
- read more
- MELANOMA Neoadjuvant administration of the oncolytic virus T-VEC improved OS in advanced melanoma.
- Dec. 9, 2019
- read more
- COLORECTAL CANCER: Integrated biomarker analysis of a large patient cohort highlights fibroblast and CD8+ lymphocyte infiltration as predictive variables.
- Dec. 9, 2019
- read more
- LUNG CANCER: New drugs targeting EGFR (lazertinib) and ALK/ROS1 (lorlatinib) have shown efficacy in phase 1/2 trials in NSCLC.
- Dec. 9, 2019
- read more
- IMPROVED SURVIVAL? The addition of VEGF inhibition to EGFR inhibition for patients with EGFR-mutant NSCLC delivered improved PFS in a phase 3 RCT...
- Dec. 9, 2019
- read more
- LUNG CANCER Patients with very high PD-L1 expression (>90%) show particularly good response to PD-1 inhibition compared to lower expressing tumours.
- Dec. 9, 2019
- read more
- HEPATOCELLULAR CANCER A novel small molecule targeting the FGF19-FGFR4 axis has entered early clinical trial in hepatic and other cancers
- Dec. 9, 2019
- read more
- VEGF as a therapeutic target The VEGF-A inhibitor bevacizumab is approved in 11 cancer types, but has failed to improve overall survival in 9 of these.
- Dec. 2, 2019
- read more
- COLORECTAL CANCER: Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- Dec. 2, 2019
- read more
- HEAD & NECK CANCER: In the phase 3 KEYNOTE-048 trial, pembrolizumab (aPD-1) plus chemotherapy was superior as first line therapy to cetuximab plus chemotherapy in patients with metastatic or locally incurable recurrent disease, regard
- Dec. 2, 2019
- read more
- CNS CANCER: Phase I clinical data from patients with low grade glioma receiving vorasidenib or vosidenib confirm early suggestions of efficacy.
- Dec. 2, 2019
- read more
- LUNG CANCER: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- Dec. 2, 2019
- read more
- IMMUNOTHERAPY: Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
- Nov. 25, 2019
- read more
- RENAL CANCER: Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- Nov. 25, 2019
- read more
- LUNG CANCER: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
- Nov. 25, 2019
- read more
- MELANOMA: Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma
- Nov. 25, 2019
- read more
- Efficacy of Pembrolizumab in Patients With Noncolorectal High MSI/Mismatch Repair–Deficient Cancer
- Nov. 18, 2019
- read more
- Glioblastoma Multiforme: 80% 6-Month Progression-Free Survival In Phase 2 Study with INO-5401 In Combination with PD-1 Inhibitor (cemiplimab)
- Nov. 18, 2019
- read more
- PROSTATE CANCER: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
- Nov. 18, 2019
- read more
- Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor
- Nov. 18, 2019
- read more
- BREAST CANCER: Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
- Nov. 18, 2019
- read more
- International Alliance for Cancer Early Detection
- Nov. 12, 2019
- read more
- Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
- Nov. 12, 2019
- read more
- DCCC Danish circulating tumor DNA network (DCCC ctDNA)
- Nov. 12, 2019
- read more
- FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor–Positive (HR+) Breast Cancer
- Nov. 12, 2019
- read more
- Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program
- Nov. 12, 2019
- read more
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- Nov. 12, 2019
- read more
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- Nov. 12, 2019
- read more
- The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
- Nov. 12, 2019
- read more
- Multidimensional imaging provides evidence for down-regulation of T cell effector function by MDSC in human cancer tissue
- Nov. 4, 2019
- read more
- Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
- Nov. 4, 2019
- read more
- Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
- Nov. 4, 2019
- read more
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
- Nov. 4, 2019
- read more
- Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications
- Nov. 4, 2019
- read more
- Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses
- Nov. 4, 2019
- read more
- Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
- Nov. 4, 2019
- read more
- Three early stage clinical trials have suggested benefit of adding checkpoint inhibition to BRAF ± MEK inhibitor therapy for patients with advanced BRAF-mutant disease.
- Oct. 21, 2019
- read more
- A trial looking at avelumab and chemotherapy for bowel cancer (POLEM)
- Oct. 21, 2019
- read more
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Oct. 21, 2019
- read more
- New Studies Question Whether Novel Anti-Cancer Drugs Are Worth Their Extra Cost
- Oct. 14, 2019
- read more
- LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
- Oct. 14, 2019
- read more
- A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
- Oct. 14, 2019
- read more
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- Oct. 14, 2019
- read more
- Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
- Oct. 14, 2019
- read more
- Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations
- Oct. 14, 2019
- read more
- Breast Cancer: inactivating NF1 mutations are enriched in advanced BC and contribute to endocrine therapy resistance
- Oct. 7, 2019
- read more
- Drug targets. - Not all BRAF mutations are equal, falling into 3 different classes based on mechanism of action and therapeutic sensitivity
- Oct. 4, 2019
- read more
- Breast cancer. -Retrospective data suggest a role for mammography screening for high risk males
- Oct. 4, 2019
- read more
- Prostate cancer. -Amplification of the androgen receptor (AR) detected by ctDNA analysis is associated with poor response to anti-androgen therapy
- Oct. 4, 2019
- read more
- Lung Cancer: 3 key news from ESMO on atezolizumab (aPD-L1), Osimertinib 7 months extra survival, conflicting view on TMB
- Oct. 4, 2019
- read more
- Cholangiocarcinoma. - One third of patients with FGFR2 rearrangements showed response to targeted anti-FGFR therapy (pemigatinib) in the second line (post-chemo) setting.
- Oct. 4, 2019
- read more
- Ovarian cancer: 3 randomised controlled phase III clinical trials presented at ESMO establish the benefit of PARP inhibition ...
- Oct. 3, 2019
- read more
- OVARIAN CANCER: Maintenance therapy with the PARP inhibitor niraparib improved progression free survival; it also increased the amount of time patients were without symptoms.
- Sept. 16, 2019
- read more
- The FDA have issued a warning of rare but potentially severe lung inflammation associated with CDK4/6 inhibitor therapy (palbociclib, ibociclib, abemaciclib).
- Sept. 13, 2019
- read more
- The European Medicines Agency has followed the FDA's lead by granting tissue agnostic approval to the NTRK inhibitor larotrectinib for patients with NTRK-fusion cancers.
- Aug. 5, 2019
- read more

READ OUR FRESH

News

Key news

PRESS-RELEASE

OncoDNA extends its Clinical Decision Support Challenge (‘CDS Challenge’)

Aug. 6, 2020Read more

PRESS-RELEASE

OncoDNA extends its Clinical Decision Support Challenge (‘CDS Challenge’)

Aug. 6, 2020Read more

PRESS-RELEASE

PRESS RELEASE: Agreement to file a friendly takeover bid initiated by OncoDNA on IntegraGen to acquire all outstanding shares at a price of 2.20€ per share

July 9, 2020Read more

PRESS-RELEASE

COMMUNIQUÉ DE PRESSE: Accord en vue d’une offre publique d’achat amicale initiée par OncoDNA sur IntegraGen au prix de 2,20€ par action, portant sur la totalité du capital

July 9, 2020Read more

All news

Do you want to share some fresh news with us?